US-based pharma company Amneal may acquire Indian Epsilon pharmaceuticals
Hyderabad-based epsilon pharmaceuticals may be acquired by Amneal Pharmaceuticals LLC. Epsilon is involved in manufacturing of wide range of steriles in oncology segment and also prescription drugs for its clients on contract basis. It has a facility spanning over 20,000 sq.mts exclusively for multi-product sterile dosage form manufacturing, also has a capacity to make up to five million lyophilised vials and up to 10 million liquid filled sterile vials.
According to a report , the deal is also likely to include sale of a manufacturing facility that received approvals of the US Food and Drug Administration (US FDA). The transaction could be valued at Rs 80-100 crore.
For Amneal, the acquisition make sense as it already has presence in the generic drug manufacturing space. Also, oncology injectibles is seen as a high-growth segment, which allows higher margins compared with conventional generic products. Global injectible market is pegged at over $15 billion.
